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Monogenic diabetes represents a heterogeneous group of disorders resulting from a single gene defect leading to disruption of insulin secretion or a reduction in the number of beta cells. Despite the classification of monogenic diabetes into neonatal diabetes or maturity onset diabetes of the young (MODY) according to age of onset, not every case can be classified into those 2 groups. 
We aim to evaluate monogenic diabetes cases without a mutation in a known MODY gene diagnosed in our clinic and emphasize the characteristics of these patients.
We evaluated patients with monogenic diabetes diagnosed during the last 10 year period. Type 1 DM, MODY, and patients with negative autoantibodies and no mutation in a known gene were excluded from the study. 
Fourteen patients, aged 1 day to 11 years, were diagnosed with non-MODY monogenic diabetes. Seven of them were diagnosed after 6 months of age. Six had a KATP channel defect. Mutations in genes resulting in destruction of beta cells were detected in 7 patients, with 4 cases having a WFS1 mutation, 2 an LRBA mutation, and one CD25 deficiency caused by a homozygous IL2RA mutation. These last three patients had positive autoantibodies. Additional systemic findings were seen in 7/14 patients, with 5/7 having severe immune system dysfunction. Treatment with sulphonylurea was successful in two patients with an ABCC8 mutation. The other patients were given insulin in differing doses. Four patients died during follow-up, three of which had immune system dysfunction. 











Monogenic diabetes represents a group of heterogeneous disorders resulting from a single gene defect that either leads to disruption of insulin secretion or a reduction in the number of beta cells. This form accounts for 2-5% of all patients with diabetes (1). 
Historically, classification of monogenic diabetes was made according to age of onset: neonatal diabetes (<6 months of age) and maturity onset diabetes of the young (MODY) (>6 months and <25 years of age). 
Neonatal diabetes is a rare and potentially devastating form of diabetes (2). The most frequent genetic causes of neonatal diabetes include abnormalities in methylation of an imprinted region on chromosome 6q24, mutations in the genes encoding the subunits of the ATP-sensitive potassium (KATP) channel of the pancreatic beta cells and mutations affecting the insulin (INS) gene. Mutations in PTF1A, GCK, PDX1, FOXP3, GLIS3, HNF1B, and EIF2AK3 genes, among others, occur more rarely (2,3,4,5). 
MODY is autosomal dominantly inherited, non-insulin dependent, and usually diagnosed <25 years of age (6). It is mostly caused by mutations in HNF1A, HNF4A, GCK and HNF1B. Individuals with HNF1A and HNF4A mutations usually present with diabetes in late childhood or early adulthood and are responsive to treatment with sulphonylureas. Heterozygous mutations in GCK result in lifelong stable fasting hyperglycemia which does not require treatment. HNF1B mutations cause diabetes with malformations of the kidney and uterus, and generally require treatment with insulin (6,7). Although MODY patients are well studied, patients with monogenic diabetes not caused by MODY genes are rarely seen and have heterogenous clinical characteristics. 

It is very important to correctly diagnose monogenic diabetes as it can predict clinical course and guide treatment. Many monogenic forms of diabetes are still misclassified as type 1 or type 2 diabetes (1). Futhermore despite the classification of monogenic diabetes according to age of onset, not every case will fit into those groups and with the adoption of gene panel tests atypical cases are increasingly being identified. Recently, significant progress has been made in understanding the molecular basis of monogenic diabetes. Determining the molecular defect can lead to development of specific treatment modalities such as sulphonylurea therapy in patients with KATP channel mutations (8,9). 






We evaluated individuals with monogenic diabetes diagnosed between 2006 and 2016 in our Pediatic Endocrinology Department. Patients found to have a genetic mutation causing their diabetes along with their affected family members are reported. Genetic analysis was performed for all patients with neonatal diabetes (diabetes diagnosed <6 months of age), MODY (diagnosed <25 years, autosomal dominant inheritance and non-insulin dependent), patients with negative autoantibodies for type 1 diabetes and patients with presumed type 1 diabetes under follow-up with additional unexplained systemic findings. Patients with type 1 DM, MODY, and without a mutation identified were excluded from the study. Details on clinical presentation, birthweight and gestation, family history, clinical phenotype, biochemical data and treatment were determined for all patients. 
 
Molecular genetic analysis was undertaken by 3 different centers (Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK; Intergen Genetics Center, Ankara, Turkey; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria). According to the genetic results we grouped patients into 4 different categories: 1) Pancreatic transcription factor deficiency 2) Abnormal Beta cell function 3) Beta cell destruction without autoimmunity and 4) Beta cell destruction with autoimmunity. Additional clinical features, treatment and follow-up of patients were also evaluated. 

RESULTS: 
During the study period, 14 patients, aged 1 day to 11 years (mean 43.3 months), were diagnosed with monogenic diabetes (Table 1). Six patients were diagnosed before 6 months of age. 

Pancreatic transcription factor deficiency
A homozygous g.23508363A>G mutation within a distal pancreatic enhancer of PTF1A was identified in one patient who was consequently assigned to the Pancreatic transcription factor deficiency group. The female patient was born at 32 weeks gestation after an uneventful delivery. Birth weight was 1140 g. Parents were consanguineous/not consanguineous. The patient was diagnosed with severe hyperglycemia on the first day of life and treated with insulin. She showed features of severe malabsorbsion soon after birth. At 6 months of age she died due to an intercurrent infection.

Abnormal beta cell function
Five of the 14 patients were classified as having Abnormal beta cell function; three had a KATP channel defect and two had an INS mutation. The two siblings (patient 2 and 3) with a homozygous INS mutation (c.-331C>G) also had leukocyte adhesion deficiency type 1 (LAD1). The older sister was born at 38 weeks gestation with a birthweight of 1800g. Meningomyelocele, hydrocephaly and congenital hip dislocation were also noted. Hyperglycemia was detected at X days/weeks. Following recurrent infections after the neonatal period, immunulogical evaluation was made and LAD1 was detected. The younger sibling was born at 37 weeks of gestation (birthweight 1700 g). At two days of life she developed hyperglycemia. She also had LAD1.

Two further siblings diagnosed with hyperinsulinemic hypoglycemia in infancy (patient 4 and 5) were heterozygous for an ABCC8 missense mutation, p.Ala1367Asp (c.4100C>A). Whilst one child required diazoxide treatment, the other was well controlled by frequent feeding. After remission of the hyperinsulinemic hypoglycemia in childhood, both children were subsequently diagnosed with auto-antibody negative diabetes at the age of 10 years. The mother, a maternal aunt and the maternal grandfather were also heterozygous for the ABCC8 mutation. The mother was diagnosed with gestational diabetes during her first pregnancy at 19 years and later developed insulin-dependent diabetes. The maternal aunt and grandfather have a medical history of postprandial hypoglycemic attacks without hyperglycemia.

Patient 7 was diagnosed with neonatal diabetes on the second day of life and has been previously reported (9b). He was born after an uneventful healthy twin pregnancy at 26 weeks with a birth weight of 1060g. There was no family history of diabetes. The patient had initially been treated with subcutaneous regular insulin, then insulin glargine but severe hypoglycemic and hyperglycemic episodes occurred. During follow-up with insulin glargine treatment, minimal weight gain occurred and HbA1c levels increased from 15% to 20%. The insulin therapy was succesfully switched to oral sulfonylureas. Mutation analysis identified two novel KCNJ11 missense mutations, p.E322A and p.D352H, which were inherited in cis (on the same parental chromosome) from the non-diabetic father. During follow-up, the glibenclamide dosage was tapered gradually and at 5 months of age therapy was discontinued. Four years after the discontinuation of glibenclamide the patient remains euglycemic, confirming a diagnosis of transient neonatal diabetes.

Beta cell destruction without autoimmunity
Homozygous mutations in WFS1 resulting in Beta cell destruction without autoimmunity were detected in 4 patients (patient 11, 12, 13 and 14; mutations listed in table 1). All were diagnosed with diabetes between 21 months and 9 years of age. Diabetes was the presenting feature in 3 cases, with one patient being diagnosed at 21 months with unusual additional systemic findings (thyroid dysgenesis with ectopic thyroid, duodenal atresia, hydrocephaly, agenesis of corpus callosum, and bilateral inguinal hernia). Optic atrophy was the first symptom at 7 years of age in the fourth patient. Diabetes insipidus have not yet developed in any of the cases at the ages of 7, 8, 12 and 16 years. 

Desctruction of beta cells with autoimmunity
Three patients with mutations in genes resulting in Desctruction of beta cells with autoimmunity had positive pancreatic autoantibodies; two had a homozygous LRBA mutation (lipopolysaccharide responsive beige-like anchor protein), and one patient had CD25 deficiency resulting from a homozygous mutation in IL2RA (Interleukin -2 receptor α chain). The first patient with LRBA deficiency (Patient 8; previously reported in [reference Johnson et al 2017]) was born at 35 weeks gestation from non-consanguineous parents. His birtweight was 2650g and he also had a cleft lip. Three elder siblings had died in childhood due to complications relating to immunodeficiency and one with severe enteropathy. Our patient presented with diabetic ketoacidosis at the age of 53 days and was treated with insulin. Although he was negative for anti-GAD antibodies at admission, re-cheking showed positivity X at 3 years of age. Right hemiparesis and neuromotor retardation with additional features including thrombocytopenia and autoimmune lymphoproliferative disease were observed at the age of three years. The patient died at 3.7 years of age as a result of an intracranial haemorrhage caused by thrombocytopenia. Exome sequencing revealed compound heterozygous mutations in the LRBA gene p.D1053fs/p.S2659* (c.3156del/c.7976C>A). The second patient with LRBA deficiency (patient 9) was a female born at term to healthy consanguineous parents. Symptoms of persisting diarrhea commenced at the age of 6 months and were accompanied by severe edema due to hypoalbuminemia. At the age of 1.5 years a diagnosis of celiac disease was made and 4.5 years later the patient was diagnosed with autoimmune thyroiditis. At 9 years of age the patient was diagnosed with type 1 diabetes mellitus requiring a low dose of insulin treatment (0.1-0.2 Unit/kg/day). Gradually the patient’s condition deterioted with increasing diarrhea and severe weight loss. An intestinal biopsy at the age of 13 years showed T-cell mediated epithelium destruction caused by autoinflammatory processes. Genetic analysis of the AIRE, IL2RA, TYMP, and POLG genes for autoimmune inflammatory bowel diseases were negative by Sanger sequencing. Although several immunosuppresive drugs were tried to prevent deterioration of the intestinal manifestations, there was no clinical improvement, and severe cachexia developed. She showed intestinal pseudo-obstruction, metabolic acidosis, anemia, thrombocytopenia, and gradually multiorgan system dysfunction. Studies for immune system dysfunction revealed normal levels of serum specific immunoglobulin subtypes, normal numbers of B- and T-lymphocyte, normal number of class switched IgD2 and CD27+ B cells but increased numbers of CD21low B cells. Exome sequencing detected a homozygous LRBA mutation c.8470_8471delinsCC (p.Ile2824Pro). 

The patient with CD25 deficiency (patient 10) presented with features similar to IPEX syndrome. He showed ichtiosiform skin lesions in the neonatal period and at the age of 45 days developed diabetes. At the same time autoimmune thyroiditis and CMV pneumonia were also detected. Anti-GAD and Islet cell antibodies were positive. With low dose insulin treatment (0.3 U/kg/day) hyperglycemia was controlled. Although the patient was clinically diagnosed with IPEX syndrome, FOXP3 analysis did not decect a mutation. Further genetic analysis identified a homozygous mutation p.Q151P (c.452A>C) in IL2RA. 

Additional features and treatment
Additional systemic findings were seen in 7/14 patients; the most common feature being immune system dysfunction  (5/14; 37.5%) (Table 2). Two siblings with an INS mutation also had LAD1 that is unlikely to be related to the INS mutation. Severe immune dysfunction were detected in patients with LRBA and IL2RA mutations consistent with the reported phenotype associated with these genes. 

Transfer to sulphonylurea therapy was successful in two patients (patients 5 and 7) with a KATP channel mutation. The other patients were given insulin in very heterogenous doses. Patients with immune diysfunction also required supportive therapy. Mortality was high among patients with four individuals diyng during follow-up: the patient with a PTF1A mutation and 3 patients with regulatory T-cell disorders (patients 8, 9 and 10). 

DISCUSSION
Advancement in genetic testing helps understanding the aetiology of diabetes in patients with monogenic diabetes. Although the percentage of monogenic diabetes is low within diabetic patients, it is genetically heterogenous and caused by different mechanisms that affect pancreatic beta cells (3). Classification of monogenic diabetes according to age of onset can lead to misdiagnosis of these patients as type 1 or type 2 diabetes. 

In our cohort two siblings with an ABCC8 mutation had congenital hyperinsulinemic hypoglycemia and later developed diabetes at 10 years of age. The presence of both these disorders is very rare in patients with a KATP channel defect but is similar to the phenotype obeserved with HNF4A mutations which can cause hyperinsulinism early in life and later- onset diabetes (MODY) (10,11). The mechanisms responsible for early manifestations of excess insulin and later development of islet cell failure are still unknown. 

Mutations resulting in destruction of beta cells without autoimmunity were detected in 4 cases having a WFS1 mutation. Wolfram syndrome, also known as DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness), is a rare neurodegenerative disease with autosomal recessive inheritance (12,13). Other common manifestations of this syndrome include urinary tract abnormalities, neurogenic bladder with hydroureteronephrosis, neurodegenerative illness, psychiatric problems and hypogonadism (12,13,14). It is well known that in many patients a significant delay can occur between diagnosis of the first signs of the syndrome and the diagnosis of Wolfram syndrome. Diabetes is usually the presenting feature of the syndrome (13). In three of our cases with Wolfram syndrome, diabetes was the first manifestation, while in one case optic atrophy was the first symptom. Diagnosis of Wolfram syndrome could be made only in one case at admission because she already had optic atropy, whereas the others were diagnosed 1.5 years to 9 years after diagnosis of diabetes. Although no intervention is known to alter the progression or life expectancy in Wolfram syndrome, early intervention for the various debilitating symptoms of this disease could improve quality of life (14, 15). One of the patients with Wolfram syndrome in our cohort was born with duodenal atresia and hydrocephaly and had unusual features which made the diagnosis difficult. When diabetes was diagnosed in infancy, monogenic diabetes was suspected. After extensive genetic analsys, a mutation in WFS1 was identified. However the additional congenital abnormalities could not be explained by this mutation. Coincidentally happening of the features is likely. 

Autoimmunity was a common characteristic in our patients. Early onset diabetes with autoimmunity and additional systemic features is consistent with a clinical diagnosis of IPEX syndrome caused by a FOXP3 mutation. But there is a group of patients, defined as having IPEX-like syndrome, with clinical symptoms closely resembling IPEX syndrome without FOXP3 mutations (16). IPEX syndrome and IPEX-like disorders are mostly monogenic diseases resulting in regulatory T (Treg) cell deficiency and/or dysfunction resulting in overlapping clinical characteristics. Treg cells have a central role in peripheral immune tolerance and preventing autoimmunity (18,19). Mutations in IL2RA, STAT5b, CTLA4 and, recently, LRBA (17,18) have been identified in patients with IPEX-like disorders. To date mutations in three genes resulting in Treg cell disorders, FOXP3, IL2RA and LRBA have been shown to cause diabetes with a variable age at onset (18). In our cohort one of the patients with LRBA deficiency was diagnosed at 9 years of age, 5 years after presantion of the first symptom, whilst the other patient presented with neonatal diabetes. Our 3 patients with LRBA and IL2RA mutations had severe immune system dysfunction and autoimmunity. Deleterious LRBA mutations cause autoimmunity, immune dysfunction including defective B-cell differentiation and associated with hypogammaglobulinemia, recurrent infections and various autoimmune disorders. Clinical features can also include severe growth retardation, failure to thrive, asthma, monoarthritis, seizures, granulomatous infiltration, hepatosplenomegaly, lymphadenopathy, nephropathy, and allergic dermatitis (20,21,22,23). The symptoms in our patient with the IL2RA mutation phenotypically resembled IPEX syndrome, but no mutation was detected in FOXP3. Because lymphoctes subgroup and in vitro phytohemaglutinin response analysis revealed CD25 and CD4 deficiency, IL2RA was studied and a homozygous mutation leading to CD25 deficiency was detected.  CD25 deficiency is a very rare Treg cell disorder. IL2 has a critical role in the development and expansion of Treg cells, proliferation and development of TH1 and TH2 cells, and also the inhibition of follicular helper T cell development. Consequently patients lacking CD25 exhibit increased susceptibility to fungal, bacterial, and viral infections (17). Only a few CD25 deficient cases have been reported to date (16,24,25). The first CD25 deficient patient resembling IPEX syndrome was described by Sharfe et al (25). A second case carrying a frameshift mutation in the IL2RA gene was reported by Coudy et al at ten years later. This case was the first CD25 deficient patient having diabetes, and presented with severe diarrhea and respiratory failure within the first months of life (16). Recently, CD25 deficiency was described in a female child who developed early onset eczema and autoimmune enteropathy, CMV infection, bullous pemphigoid, autoimmune thyroiditis, and alopecia universalis (24). As far as we know our patient is the second case with neonatal diabetes described in the literature. Because of the heterogenous spectrum of clinical features resulting from Treg cell-related disorders, a precise diagnosis can be made very late. However, an early diagnosis is needed to define the right teatment for these patients. Immunosuppressive treatment generally results only in temporary relief of symptoms in the affected subjects. Often the only viable treatment option is allogenic hemopoietic stem-cell transplantation (HSCT) following non-myeloablative conditioning regimens. A promising therapy might be abetacept, a CTLA4-immunoglobulin fusion drug, which was found to result in a dramatic and sustained improvement of symptoms in patients with LRBA deficiency (25b). Unfortunately all of our patients with Treg cell disorders died during follow-up while preparing for HSCT. Although immune dysfunction is a common finding in patients with monogenic diabetes due to Treg cell disorders, in our cohort two siblings with an INS mutation also had immune dysfunction, with a diagnosis of LAD1. Monogenic diabetes and LAD1 are two unrelated disorders, and occurence in the same individual could be coincidental. LAD1 is inherited as an autosomal recessive disorder and is commonly caused by mutations in ITGB2, located on the long arm of chromosome 21q22.3 (26). The INS gene is located on a different chromosome (11p15.1) (3). Since parents are related, it is possible that both children are affected by two autosomal recessive disorders. 
As expected, the majority of patients in our cohort required insulin therapy. The doses were heterogenous in the cohort. One patient with a ABCC8 mutation and another with a KCNJ11 mutation responded well to sulphonylurea. Supportive therapy, especially in patients with Treg cell disorders and LAD1 deficiency was also required. 
In conclusion, monogenic diabetes can be diagnosed after 6 months of age, even with positive autoantibodies. Immune dysfunction was a common clinical feature identified in 35% of patients in our cohort and should therefore be investigated in all individuals with early-onset monogenic diabetes. In patients with autoimmunity/immune dysfunction and diabetes mutations in LRBA and IL2RA, in addition to FOXP3, should be considered since mutations in these genes can result in NDM and show a very heterogenous phenotype. Mortality of patients with monogenic diabetes and additional autoimmunity was high in our cohort (5/14) and is likely to reflect the multisystem nature of these conditions. In diabetic patients with additional systemic features, immune dysfunction, and atypical clinical presentation, a genetic diagnosis is clinically important as it predicts prognosis and will guide medical management. 
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Table 1: Characteristics of patients with non-MODY monogenic diabetes

Groups	Case no	Diagnosis-Genetic mutation	Age of diagnosis 	Sex	Additional features	Treatment	Follow-up
Pancreatic transcription factor 	1	PTF1A homozygousg.23508363A>Gmutation	1 day	F	Pancreatic agenesis	Insulin	Died
Abnormal beta cell function	2*	INS homozygousc.-331C>Gmutation	1.5 months	F	LAD type 1, meningomylocele	Insulin	Operated meningomylocele 
	3*	INS homozygousc.-331C>G mutation	2 days	F	LAD type 1, meningomylocele	Insulin	-
	4**	ABCC8 heterozygousp.A1367D (c.4100C>A; p.Ala1367Asp)mutation	11 years	M	Infantile hyperinsulinemic hypoglycemia	Insulin+SU	-
	5**	ABCC8 heterozygousp.A1367D (c.4100C>A; p.Ala1367Asp)mutation	9.9 years	F	Infantile hyperinsulinemic hypoglycemia	SU	-
	6	ABCC8 (c.3115G>A)mutation	25 days	M	Epilepsy	Insulin	On insulin and antiepileptic therapy
	7	KCNJ11 heterozygous p.E322A and p.D352Hmutation	2 days	M	-	SU	Transient NDM
Beta cell destruction with autoimmunity	8	LRBA homozygousp.D1053fs/p.S2659* c.3156del/c.7976C>Amutation	4.5 months	M	Inflammatory bowel disease, thrombocytopenia	Insulin	Died
	9	LRBA homozygousc.8470_8471delinsCC; p.Ile2824Promutation	9 years	F	Inflammatory bowel disease, autoimmune thyroiditis	Insulin	Died
	10	 IL2RA homozygousc.452A>C, p.Q151P	5 months	M	Inflammatory bowel disease, autoimmune thyroiditis	Insulin	Died
Beta cell destruction without autoimmunity	11	WFS1 homozygous(p.462_464del) c.1385_1393del mutation	3.34 years	F	Optic atrophy	Insulin	-
	12	WFS1 homozygousp.R177C (c.529C>T) mutation	9.56 years	F	Optic atrophy	Insulin	-
	13	WFS1 homozygousp.V412fs (c.1230_1233del) mutation	1.7 years	M	Hydrocephalus, primary hypothyroidism, intestinal atresia	Insulin	Shunt operation, intestinal revision 
	14	WFS1 homozygousc.776delT (p.I259Tfs)mutation	5 years	M	Optic atrophy	Insulin	-
M: male, F: female, SU: sulphonylurea







Table 2: Monogenic Diabetes with Immune Dysfunction
	PATIENT 8	PATIENT 9	PATIENT 10	PATIENT 2	PATIENT 3
GENETIC LESION	LRBA 	LRBA	IL2RA	INS	INS
AGE OF DIAGNOSIS	4,5 months	9 years	5 months	1.5 months	2 days
PRESENTATION	Neonatal DM with DKA	Type 1 diabetes	Neonatal DM	Neonatal DM	Neonatal DM
IMMUNE DEFICIENCY	Low IgM, low lymphocyte activation with antiCD3	CD21low B cell depletion	CD4+CD25+cell depletion,neutropenia	Leukocyte adhesion defect type1	Leukocyte adhesion defect type1
SYSTEMIC FEATURES	Inflammatory bowel disease, thrombocytopenia	Imflammatory bowel disease, autoimmune thyroiditis	Imflammatory bowel disease, autoimmune thyroiditis, thrombocytopenia	Meningomyelocel	-
PROGNOSIS	Died	Died	Died	On insulin treatment	On insulin treatment









